Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-626-1 | CAS number: 98-00-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
Two-year inhalation carcinogenicity studies with furfuryl alcohol are available, plus rat and mouse oral (gavage) carcinogenicity studies with furfural, the proximate metabolite. These provide limited evidence of carcinogenicity at dose levels associated with systemic toxicity and only in tissues which exhibit significant tissue damage (i.e. nose and kidney for furfuryl alcohol, liver for furfural). As tumours were associated with tissue damage and furfuryl alcohol is assessed to be not genotoxic, it may be concluded that the tumours are induced by a non-genotoxic mechanism. The reported LOAEC for nasal tissue non-neoplastic lesions was 2 ppm (8 mg/m3), however the changes at this concentration may be viewed as adaptive and non-adverse.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 53 mg/kg bw/day
Carcinogenicity: via inhalation route
Endpoint conclusion
- Dose descriptor:
- LOAEC
- 8 mg/m³
Justification for classification or non-classification
The classification for carcinogenicity laid down in Annex I ATP TC C&L is: Carc. Cat 3. Although limited evidence of carcinogenicity was seen as an increase in the incidence of tumours at toxic dose levels and associated with tissue damage a classification of Carc Cat 3 R40 is considered appropriate based on the avalable data. Under Reg(EC) 1272/2008 the appropriate classification is Cat 2 H351 “Suspected of causing cancer”.
Additional information
Two-year inhalation carcinogenicity studies with furfuryl alcohol are available, plus rat and mouse oral (gavage) carcinogenicity studies with the proximate metabolite, furfural.
Inhalation
In the two year rat inhalation study with furfuryl alcohol (NTP, 1999) all male rats at 32 ppm died by week 99. There were no exposure related clinical findings and mean body weights of 32 ppm males were reduced. Increased severity of nephropathy was noted in both males and females at 32 ppm. Local toxicity including non-neoplastic lesions in nasal tissue was noted at all dose levels (LOAEC 2 ppm, equivalent to 8 mg/m3). Neoplastic effects in males included an increased incidence of adenoma, carcinoma or squamous cell carcinomas in nasal tissue at 32 ppm, and of renal tubule adenoma at 32 ppm. In females, no clear neoplastic effects were seen. The NOAEC for systemic toxicity was 8 ppm (32 mg/m3).
In the mouse inhalation carcinogenicity study with furfuryl alcohol there was an increased incidence of renal tubule neoplasms at 32 ppm. There was no evidence of carcinogenic activity of furfuryl alcohol in females. Exposure of mice to furfuryl alcohol was associated with increased incidences of non-neoplastic lesions of the nose at 2, 8 or 32 ppm in both sexes, increased severities of nephropathy at 32 ppm in males and corneal degeneration at 32 ppm in females. The reported LOAEC for local toxicity was 2 ppm (8 mg/m3) and the NOAEC for systemic toxicity was 8 ppm (32 mg/m3).
The 'adversity' of the furfuryl alcohol induced pathological changes in the nose in both rats and mice in the NTP study are considered below using the criteria described by ECETOC (ECETOC, 2002).
In the rat some changes, in particular a low incidence of combined malignant tumours in males at the high dose (128 mg/m3) are clearly adverse. In contrast, at the low dose (8 mg/m3) most of the nasal changes observed at the high (effect) dose have either a zero incidence (hyperplasia of glands, squamous metaplasia of respiratory epithelium, adenoma and carcinoma of respiratory epithelium) or an incidence and severity similar to that in the unexposed control group (suppurative inflammation, lateral wall squamous metaplasia, hyperplasia / fibrosis of olfactory epithelium). The exceptions to the above are hyperplasia of the lateral wall, atrophy and metaplasia of olfactory epithelium, and hyperplasia of respiratory epithelium where the incidences at 8 mg/m3 were statistically significantly increased compared to the control rats. Although the incidences were increased, the severity was similar to the controls. Atrophy of olfactory epithelium with metaplasia to a respiratory type epithelium is a common defensive (adaptive) response to inhaled irritants. The only neoplastic diagnosis at 8 mg/m3 is an adenoma of the lateral wall in a male rat. Although the historical control incidence of this tumour type is not recorded in the report, the absence of similar tumours in the 16 and 128 mg/m3 groups indicates that this is an incidental finding and the tumour is not related to furfuryl alcohol exposure.
In mice, the nasal findings are similar to the rat. Lesions considered to be adverse e.g. necrosis of respiratory epithelium, are not present in the 8 mg/m3 group. There are no neoplastic findings at any dose level. Treatment related findings at 8 mg/m3 e.g. metaplasia of olfactory epithelium, hyaline degeneration of respiratory epithelium are of minimal severity.
In summary, in both sexes of rats and mice, there are some changes in the nasal epithelium which are statistically significantly increased compared to the corresponding controls and are treatment related. However the nature and severity of the treatment related changes indicates that they were not adverse, but rather adaptive changes that are considered not toxicologically relevant. The furfuryl alcohol study report notes that the hyperplasia and squamous metaplasia represent conversion of highly specialised nasal tissue into a more resistant type of epithelium, representing an adaptive response to chronic irritation (NTP, 1999). In addition to the type of lesion, the limited severity of the changes (ECETOC, 2002) is a very important consideration in reaching the conclusion that they are non-adverse.
All the treatment related changes at 8 mg/m3 were consistently in the minimal/slight range of severity i. e. below a threshold of concern when compared with controls.
It is concluded that the treatment related nasal tissue findings in both rats and mice exposed to 8 mg furfuryl alcohol/m3 were of minor severity and considered to be adaptive in nature. Hence 8 mg/m3may be regarded as a 'NOAEC' for assessment of a DNEL for long term local effects.
Oral
Oral carcinogenicity studies with furfural in rats and mice (NTP, 1990) showed some evidence of carcinogenic activity for male rats, based on the occurrence of uncommon cholangiocarcinomas in two animals and bile duct dysplasia with fibrosis in two other animals at the high dose of 60 mg/kg bw/day. In mice there was an increased incidence of hepatocellular adenoma at the highest dose (175 mg/kg bw/day). These carcinomas were associated with hepatotoxicity (chronic inflammation and pigmentation) which was also seen at 100 mg/kg bw/day
Conclusion
These studies provide limited evidence of carcinogenicity at dose levels associated with systemic toxicity and only in tissues which exhibit significant tissue damage (i.e. nose and kidney for furfuryl alcohol, liver for furfural). The kidney tumours seen in the inhalation studies were at an incidence similar to the overall background range and are considered likely to have arisen as an exacerbation of the common rodent specific age-related phenomenon of chronic progressive nephropathy and thus not to be relevant to human risk assessment. As tumours were associated with tissue damage and there is no evidence of genotoxicity it may be concluded that the tumours are induced by a non-genotoxic mechanism. This interpretation is supported by the final Risk Assessment Report on Furfural published by the EU in 2008 (EU RAR, 2008) which concluded “Therefore, it is assumed that the observed liver tumours were induced via some mechanism involving liver toxicity, and that at levels at which no liver toxicity is induced, tumours will not arise. Hence, as starting point for the risk characterisation for carcinogenicity the oral NOAEL for liver toxicity by the relevant route of administration … is taken”. Therefore, the oral NOAEL of 53 mg/kg bw/day from the dietary repeated dose toxicity study (Jonker, 2000a,b) is used as the starting point for both oral and inhalation DNEL determination.
Reference:
ECETOC (2002) Recognition of, and differential between, Adverse and Non-Adverse effects in toxicology studies. Technical Report No 85, Brussels
Carcinogenicity: via oral route (target organ): digestive: liver
Carcinogenicity: via inhalation route (target organ): respiratory: nose
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.